Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre–existing chronic obstructive pulmonary diseases

References

• Graziani D, Soriano JB, Del Rio-Bermudez C, et al. Characteristics and prognosis of COVID-19 in patients with COPD. J Clin Med. 2020;9(10):3259. doi: 10.3390/jcm9103259
   PubMed Web of Science ®Google Scholar
• Calver JF, Fabbri L, May J, et al. COVID-19 in patients with chronic lung disease. Clin Chest Med. 2023;44(2):385–393. doi: 10.1016/j.ccm.2022.11.013
   PubMed Web of Science ®Google Scholar
• Singh D, Mathioudakis AG, Higham A. Chronic obstructive pulmonary disease and COVID-19: interrelationships. Curr Opin Pulm Med. 2022;28(2):76–83. doi: 10.1097/MCP.0000000000000834
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Inoue H. Viral infections in asthma and COPD. Respir Investig. 2014;52(2):92–100. doi: 10.1016/j.resinv.2013.08.005
   PubMedGoogle Scholar
• Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924
   PubMed Web of Science ®Google Scholar
• Rainer L, Bachner F, Eglau K, et al. Comorbidities and COVID-19 hospitalization, ICU admission and hospital mortality in Austria : aretrospective cohort study. Wien Klin Wochenschr. 2022;134(23-24):856–867.
   Google Scholar
• Gómez Antúnez M, Muiño Míguez A, Bendala Estrada AD, et al. Clinical characteristics and prognosis of COPD patients hospitalized with SARS-CoV-2. Int J Chron Obstruct Pulmon Dis. 2020;15:3433–3445. doi: 10.2147/COPD.S276692
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Rabe AP, Loke WJ, et al. Epidemiology, healthcare resource utilization, and mortality of asthma and COPD in COVID-19: a systematic literature review and meta-analyses. J Asthma Allergy. 2022;15:811–825. doi: 10.2147/JAA.S360985
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen IT, Chao CM, et al. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines. 2021;20(8):1013–1025. doi: 10.1080/14760584.2021.1949293
   PubMed Web of Science ®Google Scholar
• Lai CC, Chao CM, Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021;54(5):767–775. doi: 10.1016/j.jmii.2021.05.011
   PubMedGoogle Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044
   PubMed Web of Science ®Google Scholar
• Rabie AM. Future of the current anticoronaviral agents: a viewpoint on the validation for the next COVIDs and pandemics. Biocell. 2023;47(10):2133–2139. doi: 10.32604/biocell.2023.030057
   Web of Science ®Google Scholar
• Rabie AM. Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication. ACS Omega. 2022;7(3):2960–2969. doi: 10.1021/acsomega.1c05998
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdalla M. Forodesine and riboprine exhibit strong anti-SARS-CoV-2 repurposing potential: in silico and in vitro studies. ACS Bio Med Chem Au. 2022;2(6):565–585. doi: 10.1021/acsbiomedchemau.2c00039
   PubMedGoogle Scholar
• Eltayb WA, Abdalla M, Rabie AM. Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species. ACS Omega. 2023;8(6):5234–5246. doi: 10.1021/acsomega.2c03881
   PubMedGoogle Scholar
• Rabie AM. Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoVitris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs. New J Chem. 2021;45(2):761–771. doi: 10.1039/D0NJ03708G
   Web of Science ®Google Scholar
• Rabie AM. Teriflunomide: a possible effective drug for the comprehensive treatment of COVID-19. Curr Res Pharmacol Drug Discov. 2021;2:100055. doi: 10.1016/j.crphar.2021.100055
   PubMedGoogle Scholar
• Rabie AM, Eltayb WA. Potent dual polymerase/exonuclease inhibitory activities of antioxidant aminothiadiazoles against the COVID-19 omicron virus: a promising in Silico/in vitro repositioning research study. Mol Biotechnol. 2024;2023(4):1–20. doi: 10.1007/s12033-022-00551-8
   Google Scholar
• Rabie AM. Efficacious preclinical repurposing of the nucleoside analogue Didanosine against COVID-19 polymerase and exonuclease. ACS Omega. 2022;7(25):21385–21396. doi: 10.1021/acsomega.1c07095
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdalla M. Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the omicron-B.1.1.529/BA.2 subvariant: a repurposing research study. Med Chem Res. 2023;32(2):326–341. doi: 10.1007/s00044-022-02970-3
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdel-Dayem MA, Abdalla M. Promising experimental anti-SARS-CoV-2 agent “SLL-0197800”: the prospective universal inhibitory properties against the coming versions of the coronavirus. ACS Omega. 2023;8(39):35538–35554. doi: 10.1021/acsomega.2c08073
   PubMed Web of Science ®Google Scholar
• Rabie AM. The informative nature of the disappeared SARS-CoV-2 genomic sequences: a mini-review with perspectives. Adv Cryog Res [Internet]. 2022;1:58–64. doi: 10.37256/acbr.1220221403
   Google Scholar
• Rabie AM. RNA: the most attractive target in recent viral diseases. Chem Biol Drug Des. 2024;103:e14404. doi: 10.1111/cbdd.14404
   PubMed Web of Science ®Google Scholar
• Rabie AM. New potential inhibitors of coronaviral main protease (CoV-mpro): strychnine bush, pineapple, and ginger could be natural enemies of COVID-19. Int J New Chem. 2022;9:225–237. doi: 10.22034/ijnc.2022.3.10
   Google Scholar
• Rabie AM. Potent toxic effects of taroxaz-104 on the replication of SARS-CoV-2 particles. Chem Biol Interact. 2021;343:109480. doi: 10.1016/j.cbi.2021.109480
   PubMed Web of Science ®Google Scholar
• Rabie AM. Improved synthesis of the anti-SARS-CoV-2 investigational agent (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20). Rev Chim. 2022;73(4):69–75. doi: 10.37358/RC.22.4.8555
   Google Scholar
• Kwok WC, Tsoi MF, Leung SHI, et al. Real-world study on effectiveness of molnupiravir and nirmatrelvir-ritonavir in unvaccinated patients with chronic respiratory diseases with confirmed SARS-CoV-2 infection managed in out-patient setting. Viruses. 2023;15(3):610.
   Web of Science ®Google Scholar
• Palchuk MB, London JW, Perez-Rey D, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6(2):ooad035. doi: 10.1093/jamiaopen/ooad035
   PubMedGoogle Scholar
• Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130–140. doi: 10.1016/S2215-0366(20)30462-4
   PubMed Web of Science ®Google Scholar
• Hsu WH, Shiau BW, Tsai YW, et al. The effect of molnupiravir on post-acute outcome of COVID-19 survivors. J Infect. 2023;87(4):339–343. doi: 10.1016/j.jinf.2023.03.016
   PubMed Web of Science ®Google Scholar
• Hsu WH, Tsai YW, Wu JY, et al. Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors. J Infect. 2023;86(4):e107–e10. doi: 10.1016/j.jinf.2023.02.007
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi: 10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Marshall SW. Power for tests of interaction: effect of raising the type I error rate. Epidemiol Perspect Innov. 2007;4(1):4. doi: 10.1186/1742-5573-4-4
   PubMedGoogle Scholar
• Hsu WH, Shiau BW, Liu TH, et al. Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis. Expert Rev Anti Infect Ther. 2023;21(10):1143–1151. doi: 10.1080/14787210.2023.2267846
   PubMed Web of Science ®Google Scholar
• Tsai YW, Wu JY, Liu TH, et al. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data. J Med Virol. 2023;95(6):e28869. doi: 10.1002/jmv.28869
   PubMed Web of Science ®Google Scholar
• Wu JY, Liu MY, Liu TH, et al. Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19. J Med Virol. 2023;95(6):e28866. doi: 10.1002/jmv.28866
   PubMed Web of Science ®Google Scholar
• Wu JY, Liu MY, Liu TH, et al. Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19. Int J Antimicrob Agents. 2023;62(6):106984. doi: 10.1016/j.ijantimicag.2023.106984
   PubMed Web of Science ®Google Scholar
• Tsang NNY, So HC, Cowling BJ, et al. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infect Dis. 2023;23(4):421–434. doi: 10.1016/S1473-3099(22)00732-0
   PubMed Web of Science ®Google Scholar
• Drenko P, Kacer M, Kielberger L, et al. Safety and efficacy of one and two booster doses of SARS-CoV-2 mRNA vaccines in kidney transplant recipients: a randomized clinical trial. Transpl Infect Dis. 2023;25(5):e14150. doi: 10.1111/tid.14150
   PubMed Web of Science ®Google Scholar
• Shannon A, Canard B. Kill or corrupt: mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2. Antiviral Res. 2023;210:105501. doi: 10.1016/j.antiviral.2022.105501
   PubMed Web of Science ®Google Scholar
• Pochtovyi AA, Kustova DD, Siniavin AE, et al. In vitro efficacy of antivirals and monoclonal antibodies against SARS-CoV-2 omicron lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1. Vaccines (Basel). 2023;11(10):1533. doi: 10.3390/vaccines11101533
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Therapeutic management of nonhospitalized adults with COVID-19. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/
   Google Scholar
• Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2022 Sep5:ciac724. doi: 10.1093/cid/ciac724
   Google Scholar